ORKA (Oruka Therapeutics) Accounts Payable & Accrued Expense : $10.79 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Accounts Payable & Accrued Expense?

Oruka Therapeutics's quarterly accounts payable & accrued expense stayed the same from . 20 ($0.00 Mil) to . 20 ($0.00 Mil) but then increased from . 20 ($0.00 Mil) to Dec. 2024 ($10.79 Mil).

Oruka Therapeutics's annual accounts payable & accrued expense stayed the same from . 20 ($0.00 Mil) to . 20 ($0.00 Mil) but then increased from . 20 ($0.00 Mil) to Dec. 2024 ($10.79 Mil).

Oruka Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Oruka Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Accounts Payable & Accrued Expense Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Accounts Payable & Accrued Expense

10.79

Oruka Therapeutics Semi-Annual Data
	Dec24
Accounts Payable & Accrued Expense	10.79

Oruka Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

HQ1:Germany

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.